HSK39297 tablets + Eculizumab Injection
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout HSK39297 tablets + Eculizumab Injection
HSK39297 tablets + Eculizumab Injection is a phase 3 stage product being developed by Haisco Pharmaceutical Group for PNH. The current trial status is completed. This product is registered under clinical trial identifier NCT06799546. Target conditions include PNH.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06799546 | Phase 3 | Completed |
Competing Products
20 competing products in PNH
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| REGN3918 | Regeneron Pharmaceuticals | Phase 2 | 51 |
| ALN-CFB + Placebo | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| HSK39297 tablets + HSK39297 tablets + HSK39297 tablets | Haisco Pharmaceutical Group | Phase 1 | 30 |
| HSK39297 tablets | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Carbon-14 labeled HSK39297 | Haisco Pharmaceutical Group | Phase 1 | 30 |
| HSK39297 | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Zilucoplan (RA101495) | UCB | Phase 2 | 49 |
| Zilucoplan (RA101495) | UCB | Phase 2 | 49 |
| Zilucoplan (RA101495) | UCB | Phase 2 | 49 |
| ALN-CC5 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Placebo + BCX9930 monotherapy | BioCryst Pharmaceuticals | Phase 2 | 47 |
| Eculizumab + Ravulizumab + BCX9930 | BioCryst Pharmaceuticals | Phase 2 | 47 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 2 | 47 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 2 | 47 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 1 | 28 |